Hubei University of Chinese Medicine, Wuhan, 430065, China.
Hepatopathy Institute, Affiliated Hospital of Hubei University of Chinese Medicine (Chinese Medicine Hospital in Hubei Province), Wuhan, 430061, China.
Front Med. 2017 Jun;11(2):191-202. doi: 10.1007/s11684-017-0512-0. Epub 2017 Mar 27.
Primary hepatic carcinoma (PHC) is a common malignant tumor in China. Cancer is comprehensively treated with various therapeutic regimes, including traditional Chinese medicine (TCM). TCM has been widely used to improve the quality of life, delay the time of cancer progression, and prolong the median survival time. This systematic review with meta-analysis aimed to assess the effect of TCM combined with Western therapy on primary hepatic carcinoma. A comprehensive literature search was conducted in six databases, including CNKI, VIP, Wan-Fang Database, CBM, PubMed, and Cochrane library. A total of 44 randomized controlled trials (RCTs) involving 3429 participants suffering from PHC were selected. Meta-analysis results indicated that the overall effect of TCM and Western integrative treatment on PHC was higher than that of Western intervention alone, which can postpone tumor recurrence and metastasis and prolong the overall survival time of patients with PHC. Although the obtained evidence remained weak because of the poor methodological quality of the included studies, this review provided relevant data supporting the efficacy and safety of TCM combined with Western therapies. In future research, individual RCT studies should incorporate accepted standards for trial design and reporting, proper outcome indicators according to international standards, blinding in allocation concealment, and valid follow-up periods.
原发性肝癌(PHC)是中国常见的恶性肿瘤。癌症采用包括中医(TCM)在内的多种治疗方案综合治疗。中医已广泛用于提高生活质量、延缓癌症进展时间和延长中位生存时间。本系统评价和荟萃分析旨在评估 TCM 联合西医治疗原发性肝癌的效果。在六个数据库(CNKI、VIP、万方数据库、CBM、PubMed 和 Cochrane library)中进行了全面的文献检索,共筛选出 44 项随机对照试验(RCT),涉及 3429 名 PHC 患者。荟萃分析结果表明,TCM 和西医综合治疗对 PHC 的总体疗效高于西医单独干预,可延缓肿瘤复发转移,延长 PHC 患者的总生存时间。尽管由于纳入研究的方法学质量较差,获得的证据仍然较弱,但本综述提供了支持 TCM 联合西医治疗的疗效和安全性的相关数据。在未来的研究中,应根据国际标准纳入公认的试验设计和报告标准、适当的结局指标、分配隐匿的盲法和有效的随访期。